Mr Quinn will continue to focus on the strategic development of Clenergen, as well as being responsible for business development.
Tim Bowen, who has been serving as the company’s chief operating officer, will assume the position of chief executive officer and be responsible for the day-to-day management of Clenergen.
Dr Arvind Pandalai, who previously served as the company’s non-executive group chairman, will assume the position of the non-executive chairman of the board of the company’s wholly-owned subsidiary Clenergen India.
Mr Bowen said, “Mark Quinn’s historic role with our company and its predecessor business has been all encompassing. As Clenergen continues to strengthen its management team as its operations come ‘on-line,’ we expect Mark’s involvement as executive chairman will allow him to continue to provide us with his management oversight while also allowing him to devote additional time and effort to the further strategic development of our company.
“We believe that the management changes will assist the company in successfully executing its business plan and that Clenergen is now well positioned to deliver real shareholder value in the near future.”
